Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Acad Dermatol ; 74(2): 231-44; quiz 245-6, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26775773

ABSTRACT

There are a significant number of diseases and treatment considerations of considerable importance relating to the skin and renal systems. This emphasizes the need for dermatologists in practice or in clinical training to be aware of these associations. Part I of this 2-part continuing medical education article reviews the genetic syndromes with both renal and cutaneous involvement that are most important for the dermatologist to be able to identify, manage, and appropriately refer to nephrology colleagues. Part II reviews the inflammatory syndromes with relevant renal manifestations and therapeutic agents commonly used by dermatologists that have drug-induced effects on or require close consideration of renal function. In addition, we will likewise review therapeutic agents commonly used by nephrologists that have drug-induced effects on the skin that dermatologists are likely to encounter in clinical practice. In both parts of this continuing medical education article, we discuss diagnosis, management, and appropriate referral to our nephrology colleagues in the context of each nephrocutaneous association. There are a significant number of dermatoses associated with renal abnormalities and disease, emphasizing the need for dermatologists to be keenly aware of their presence in order to avoid overlooking important skin conditions with potentially devastating renal complications. This review discusses important nephrocutaneous disease associations with recommendations for the appropriate urgency of referral to nephrology colleagues for diagnosis, surveillance, and early management of potential renal sequelae.


Subject(s)
Genetic Diseases, Inborn/genetics , Kidney Diseases/genetics , Leiomyomatosis/genetics , Skin Diseases/genetics , Skin Neoplasms/genetics , Uterine Neoplasms/genetics , von Hippel-Lindau Disease/genetics , Beckwith-Wiedemann Syndrome/complications , Beckwith-Wiedemann Syndrome/genetics , Beckwith-Wiedemann Syndrome/therapy , Birt-Hogg-Dube Syndrome/complications , Birt-Hogg-Dube Syndrome/genetics , Birt-Hogg-Dube Syndrome/therapy , Fabry Disease/complications , Fabry Disease/genetics , Fabry Disease/therapy , Genetic Diseases, Inborn/therapy , Hamartoma Syndrome, Multiple/complications , Hamartoma Syndrome, Multiple/genetics , Hamartoma Syndrome, Multiple/therapy , Humans , Leiomyomatosis/complications , Leiomyomatosis/therapy , Mutation , Nail-Patella Syndrome/complications , Nail-Patella Syndrome/genetics , Nail-Patella Syndrome/therapy , Neoplastic Syndromes, Hereditary , Neurofibromatosis 1/complications , Neurofibromatosis 1/genetics , Neurofibromatosis 1/therapy , Skin Neoplasms/complications , Skin Neoplasms/therapy , Tuberous Sclerosis/complications , Tuberous Sclerosis/genetics , Tuberous Sclerosis/therapy , Turner Syndrome/complications , Turner Syndrome/genetics , Turner Syndrome/therapy , Uterine Neoplasms/complications , Uterine Neoplasms/therapy , von Hippel-Lindau Disease/complications , von Hippel-Lindau Disease/therapy
2.
J Am Acad Dermatol ; 74(2): 247-70; quiz 271-2, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26775774

ABSTRACT

There are a significant number of dermatoses associated with renal abnormalities and disease, and dermatologists need to be keenly aware of their presence in order to avoid overlooking important skin conditions with potentially devastating renal complications. This review discusses important nephrocutaneous disease associations and recommendations for the appropriate urgency of referral to nephrology colleagues for diagnosis, surveillance, and early management of potential renal sequelae. Part II of this 2-part continuing medical education article addresses inflammatory and medication-related nephrocutaneous associations.


Subject(s)
Antihypertensive Agents/adverse effects , Drug Eruptions/etiology , Inflammation/complications , Renal Insufficiency, Chronic/chemically induced , Skin Diseases/etiology , Skin Diseases/therapy , Anti-Bacterial Agents/adverse effects , Dermatologic Agents/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Renal Insufficiency, Chronic/complications , Skin Diseases/pathology
3.
Expert Rev Clin Immunol ; 10(2): 189-202, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24410536

ABSTRACT

Ustekinumab is a fully human monoclonal antibody directed against the p40 subunit shared by interleukin 12 and interleukin 23, two naturally occurring protein regulators that play an important role in immune-mediated inflammatory diseases, including psoriatic arthritis (PsA). In September of 2009, the US FDA approved ustekinumab for the treatment of adult patients with moderate to severe plaque psoriasis. Beginning in November of 2009, Janssen Biotech (formerly Centocor Biotech), the developer of ustekinumab, initiated clinical trials to investigate the efficacy of ustekinumab in the treatment of other inflammatory disorders, including PsA. Phase II and Phase III studies showed both a good safety profile and significant efficacy for ustekinumab in the treatment of PsA, leading to the drug's approval in both Europe and the USA. In an immunotherapy market currently dominated by anti-TNF-α drugs for the treatment of PsA, ustekinumab offers an alternative option for patients with PsA, including those unresponsive to methotrexate and the TNF-α inhibitory agents currently approved for this potentially debilitating disease.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/therapy , Immunotherapy/methods , Tumor Necrosis Factor-alpha/metabolism , Animals , Clinical Trials as Topic , Drug Approval , Europe , Humans , Tumor Necrosis Factor-alpha/immunology , United States , Ustekinumab
4.
Proc (Bayl Univ Med Cent) ; 25(2): 155-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22481847

ABSTRACT

Bullous pemphigoid is an autoimmune disease of the skin characterized by large, tense bullae resulting in significant morbidity in affected individuals. The diagnosis of bullous pemphigoid may present challenges due to clinical similarities with various other bullous eruptions. Frequently, epidemiological features can provide clues to the diagnosis of bullous pemphigoid, with histologic analysis commonly required for definitive diagnosis. This case study illustrates the typical clinical and histologic findings seen in bullous pemphigoid patients and briefly discusses the differential diagnosis. An in-depth understanding of the intricate pathophysiology is essential in order to educate patients. After diagnosis and appropriate workup, an array of treatment approaches, including topical and systemic corticosteroids, immunosuppressive agents, antibiotics, chemotherapeutic agents, and even monoclonal antibodies, may be utilized individually or in combination to achieve an optimal therapeutic response.

SELECTION OF CITATIONS
SEARCH DETAIL
...